XM nie świadczy usług obywatelom Stanów Zjednoczonych.
A
A

Abbott


Wiadomości

GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales

GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales BENGALURU, May 17 (Reuters) - Drugmaker GlaxoSmithKline Pharma India GLAX.NS reported a 49% rise in fourth-quarter adjusted profit on Friday , as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. The company reported consolidated profit before exceptional items and taxes of 2.68 billion rupees ($32.1 million) for the quarter ended March 31, compared to 1.
A
G

Indian shares see worst week since mid-March as volatility, foreign selling weighs

INDIA STOCKS-Indian shares see worst week since mid-March as volatility, foreign selling weighs Updates with closing levels at 3:30 p.m. IST By Bharath Rajeswaran and Hritam Mukherjee BENGALURU, May 10 (Reuters) - Indian shares ended higher on Friday, but logged their worst week in eight as concerns over the outcome of ongoing national elections and selling by foreign investors weighed on sentiment .
A

Abbott India up after Q4 profit rise, top pharma index gainer

BUZZ-Abbott India up after Q4 profit rise, top pharma index gainer ** Shares of Abbott India ABOT.NS up 3.5%, after a 4.8% climb earlier in the session ** Drugmaker reported 24% rise in profit while rev rose 7% ** Brokerage CLSA sees sustained growth for the Digene antacid maker, retains "outperform" rating and 27,780 rupees PT ** ABOT top pct gain
A

Drugmaker Abbott India posts Q4 profit rise on higher sales

Drugmaker Abbott India posts Q4 profit rise on higher sales BENGALURU, May 9 (Reuters) - Indian drugmaker Abbott India ABOT.NS reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines. The company, which makes the popular antacid medicine Digene, said its profit rose to 2.87 billion rupees ($34.3 million) for the three months ended March 31, from 2.31 billion rupees a year earlier.
A
G

India economic, corporate events on May 9

DIARY- India economic, corporate events on May 9 BENGALURU, May 9 (Reuters) - Diary of India economic, corporate events on May 9. ECONOMIC, CORPORATE .BSE500 EVENTS: Date Time RIC Company Name Event Name 09-May-2024 NTS ALKY.NS Alkyl Amines Chemicals Ltd Q4 2024 Alkyl Amines Chemicals Ltd Earnings Release 09-May-2024 NTS ABOT.NS Abbott India Ltd Q4
A

Baxter raises annual profit forecast on strong demand for medical devices

REFILE-Baxter raises annual profit forecast on strong demand for medical devices Corrects to add story keyword used by media customers May 2 (Reuters) - Medical device maker Baxter International BAX.N raised its annual profit forecast and beat quarterly estimates on Thursday, banking on strong demand for its infusion pumps and dialysis products. Investor expectations around the performance of medical device makers have been heightened since last November due to higher demand for procedures, espe
A
S

Becton Dickinson lifts profit view on strong surgical equipment demand

Becton Dickinson lifts profit view on strong surgical equipment demand May 2 (Reuters) - Becton Dickinson BDX.N raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes. Medical technology firms like Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, undergo surgeries that were put on hold during the
A
B
T

Edwards Lifesciences first-quarter profit beats estimates on heart devices strength

Edwards Lifesciences first-quarter profit beats estimates on heart devices strength April 25 (Reuters) - Edwards Lifesciences Corp EW.N on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices. The California-based company now expects annual sales growth to be at the higher end of its 8% to 10% forecast.
A

U.S. American Express, Philip Morris, Royal Gold

U.S. RESEARCH ROUNDUP-American Express, Philip Morris, Royal Gold April 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American Express, Philip Morris and Royal Gold, on Monday. HIGHLIGHTS * American Express Co AXP.N : TD Cowen raises target price to $225 from $221 * Philip Morris PM.N : Jefferies raises target price to $101 from $98 * PPG Industries Inc PPG.N : Evercore ISI cuts to in line from outperform * Roya
A
A
A
A
B
B
C
C
D
E
H
I
L
F
U
A
A
C

U.S. Builders Firstsource, Eli Lilly, Northern Trust

U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust April 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Builders Firstsource, Eli Lilly and Northern Trust, on Thursday. HIGHLIGHTS * Alphabet Inc GOOGL.O : Bernstein raises target price to $165 from $160 * Builders Firstsource Inc BLDR.N : Jefferies raises target price to $237 from $226 * Coinbase Global Inc COIN.O : Bernstein raises target price
A
A
C
C
C
C
F
G
J
N
Q
S
A
L
J
A
C

Stocks decline as interest rate uncertainty, earnings weigh

US STOCKS-Stocks decline as interest rate uncertainty, earnings weigh United Airlines gains on upbeat Q2 profit forecast Travelers falls after Q1 profit miss Fed's Beige Book shows slight expansion in economic activity Indexes off: Dow 0.12%, S&P 500 0.58%, Nasdaq 1.15% Updated at 4:09 p.m. ET/ 2009 GMT By Chuck Mikolajczak NEW YORK, April 17 (Reuters) - U.S.
A
J
U
U
U

Stocks slip as interest rate uncertainty, earnings weigh

US STOCKS-Stocks slip as interest rate uncertainty, earnings weigh United Airlines gains on upbeat Q2 profit forecast Travelers falls after Q1 profit miss Fed's Beige Book shows slight expansion in economic activity Updated at 4:00 p.m. ET/ 2000 GMT By Chuck Mikolajczak NEW YORK, April 17 (Reuters) - U.S. stocks fell in choppy trading on Wednesday as investors assessed the Federal Reserve's interest rate stance and a batch of soft earnings early in the financial reporting season.
A
J
U
U
U

S&P 500, Nasdaq dip as interest rate concerns, earnings weigh

US STOCKS-S&P 500, Nasdaq dip as interest rate concerns, earnings weigh United Airlines gains on upbeat Q2 profit forecast Travelers falls after Q1 profit miss Indexes: Dow up 0.03%, S&P off 0.34%, Nasdaq 0.74% Updated at 2:30 p.m. ET/ 1830 GMT By Chuck Mikolajczak NEW YORK, April 17 (Reuters) - U.S. stocks fell in choppy trading on Wednesday as investors assessed the Federal Reserve's interest rate stance and a batch of soft earnings early in the financial reporting season.
A
J
U
U
U

Wall St slips as dour earnings, chip stocks weigh

US STOCKS-Wall St slips as dour earnings, chip stocks weigh For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. United Airlines gains on upbeat Q2 profit forecast Travelers falls after Q1 profit miss Indexes down: Dow 0.37%, S&P 0.41%, Nasdaq 0.59% Updated at 11:30 a.m. ET/ 1530 GMT By Shashwat Chauhan and Shristi Achar A April 17 (Reuters) - Wall Street's main indexes fell in choppy trading on Wednesday with chip stocks among the top loser
A
I
N
A
J
U
U
U

Abbott Laboratories reports results for the quarter ended in March - Earnings Summary

Abbott Laboratories reports results for the quarter ended in March - Earnings Summary Abbott Laboratories ABT.N reported quarterly adjusted earnings of 98 cents​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of $1.03. The mean expectation of twenty one analysts for the quarter was for earnings of 95 cents per share.
A

Abbott's device sales drive profit beat, but shares fall as forecast disappoints

UPDATE 4-Abbott's device sales drive profit beat, but shares fall as forecast disappoints Updates shares in paragraph 1, adds analyst comment in paragraphs 4 and 5 By Leroy Leo and Pratik Jain April 17 (Reuters) - Abbott Laboratories ABT.N beat Wall Street estimates for quarterly profit on Wednesday on robust sales of its medical devices, b ut the company's stock fell 3% in morning trading, signaling disappointment over its annual forecast .
A

Abbott Reports First-Quarter 2024 Results And Raises Midpoint Of Full-Year Guidance Ranges

BRIEF-Abbott Reports First-Quarter 2024 Results And Raises Midpoint Of Full-Year Guidance Ranges April 17 (Reuters) - Abbott Laboratories ABT.N : ABBOTT REPORTS FIRST-QUARTER 2024 RESULTS AND RAISES MIDPOINT OF FULL-YEAR GUIDANCE RANGES ABBOTT LABORATORIES: QTRLY EARNINGS PER SHARE $0.70 ABBOTT LABORATORIES - SEES SPECIFIED ITEMS FOR 2024 OF $1.30
A

Abbott Q1 Adjusted EPS USD 0.98 Vs. IBES Estimate USD 0.95

BRIEF-Abbott Q1 Adjusted EPS USD 0.98 Vs. IBES Estimate USD 0.95 Apr 17 (Reuters) - Abbott Q1 EPS USD 0.7. outlook FY EPS USD 3.25-3.4 outlook FY adjusted EPS USD 4.55-4.7
A

Abbott beats quarterly profit estimates on strong medical device sales

CORRECTED-Abbott beats quarterly profit estimates on strong medical device sales Corrects to first quarter from annual in paragraph 2 April 17 (Reuters) - Abbott Laboratories ABT.N beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast, as robust demand for medical procedures boosted sales of its devices, including its glucose-monitoring products.
A

Futures inch up on megacap support; earnings, Fed comments on tap

US STOCKS-Futures inch up on megacap support; earnings, Fed comments on tap For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures up: Dow 0.37%, S&P 0.29%, Nasdaq 0.10% April 17 (Reuters) - U.S. stock index futures rose on Wednesday as most megacap growth stocks gained, while investors awaited earnings and commentary from the central bank's policymakers to gauge how corporate America was faring.
A
A
M
T
U
A
J
U
U
U
U



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.